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Introduction: In North America, the majority of prospective inves-
tigation using stereotactic body radiation therapy (SBRT) for tho-
racic targets has been carried out treating medically inoperable
patients with non-small cell lung cancer.
Methods: Because SBRT involves constructing very compact high-
dose volumes within the lung for targeting cancer deposits, tumor
position must be accurately assessed throughout the respiratory
cycle. Measures to account for this motion, either by tracking
(chasing), gating, or inhibition (breath hold and abdominal compres-
sion) must be used to avoid large margins of error that would expose
uninvolved normal tissues. Sophisticated image guidance and re-
lated treatment delivery technology have been used primarily for the
purpose of targeting the tumor with as low a radiation dose to the
surrounding normal tissue as possible.
Results: Phase I dose escalation trials have been carried out in North
America to achieve potent tumorcidal dose levels capable of erad-
icating tumors with high likelihood. These studies indicate a clear
dose-response relationship for tumor control with escalating dose of
SBRT. While late toxicity requires further careful assessment, acute
and subacute toxicity are generally acceptable. Radiographic and
local tissue effects consistent with bronchial or vascular damage and
downstream collapse with fibrosis are common. While such radio-
graphic changes are most often asymptomatic, more frequent and
sometimes debilitating toxicity has been observed for patients with
tumors near the central airways.
Conclusions: Prospective trials using SBRT in North America have
been able to identify potent tolerant dose levels and confirm their
efficacy in patients with medically inoperable disease. Although
mechanisms of this injury remain elusive, ongoing prospective trials
offer the hope of finding the ideal application for SBRT in treating
pulmonary targets.
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Early-stage lung cancer has traditionally been treated withsurgery. Surgical therapy, especially when able to perform
a lobectomy or pneumonectomy, is associated with 3- to
5-year survival rates (effectively cure) of 60% to 80%.1–4
Lesser surgical therapies, like wedge resections or segmen-
tectomies, have been shown to be inferior surgical procedures
due to local recurrence and decreased survival compared with
anatomical resections.5 Alternate therapies, like convention-
ally fractionated radiotherapy (CFRT), are not nearly as
effective with 3- to 5-year survival rates of only 15% to
45%.6–12 Both selection of patients and effectiveness of
therapy account for these differences. Generally, radiotherapy-
treated patients have a host of medical problems that would
make a lobectomy or pneumonectomy intolerable including
severe pulmonary disease, heart disease, severe diabetes, or
history of stroke. These patients are called medically inoper-
able and have competing causes of death in the 3- to 5-year
period after cancer diagnosis such that survival is inherently
greatly compromised. At any rate, surgically treated patients
have enjoyed better survival compared with radiotherapy-
treated patients, justifying surgery as standard therapy.
Several prospective clinical results from trials using
stereotactic body radiation therapy (SBRT) have been pub-
lished throughout the world. In North America, cooperative
groups including the Radiation Therapy Oncology Group
(RTOG) and North Central Cancer Treatment Group (NCCTG)
are carrying out trials using SBRT in early-stage lung cancer.
The enthusiasm for SBRT centers on the observation that
small- to medium-sized tumors can be eradicated with a
noninvasive therapy. Consequential normal tissue toxic ef-
fects, although present and sometimes severe, are generally
tolerable even in the frail population treated in clinical trials
to date. Important lessons have been learned via prospective
testing with ongoing follow-up further refining the role of the
therapy. In this article, we describe the current application of
SBRT and summarize the results and conduct of prospective
clinical trials carried out in North America using SBRT for
early-stage lung cancer.
MATERIALS AND METHODS
Local versus Regional Control in Early-Stage
Lung Cancer
Both surgery and radiotherapy are modalities that pri-
marily affect local control. Both also may affect regional
control, depending on the extent of surgery or size of the
radiotherapy fields. Patients surgically treated with anatomic
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resections like lobectomy have reported local control in the
90% range.5,13 The poorer outcomes seen in surgically treated
patients undergoing limited resections like wedge are primar-
ily accounted for by failure to achieve local control. Wedge
resections, for example, are associated with a high rate of
suture line recurrence that ultimately threatens survival. Al-
though lobectomy and pneumonectomy also remove lym-
phatics in transit to the mediastinum not generally removed
by limited resections, lymphatic recurrence alone is not a
predominant failure pattern after surgical resection of any
form.5 As patients treated with conventionally fractionated
radiotherapy experience poor local control in the range of
30% to 50%, it is no wonder that the ultimate survival rates
are considerably poorer than those with surgery. Not surpris-
ingly, the addition of irradiation of the regional lymph nodes
offers no significant improvement over irradiation of the local
tumor alone.14–17
Implementing Ablative Radiotherapy
Fractionation
Failure to achieve local control with CFRT has been the
greatest shortcoming of radiotherapy as a treatment for early-
stage lung cancer. The typical treatment strategy with radio-
therapy has been to deliver approximately 60 to 66 Gy using
2-Gy fractions, which requires approximately 6 to 7 weeks of
daily treatment. There are three basic strategies for improving
local control with radiotherapy: increase the total dose, in-
crease the radiosensitivity, or increase the dose per fraction.
All these strategies have been studied in prospective trials.
Three trials in North America have examined the ef-
fects of increasing doses of CFRT. Each was originally
designed in a period before the widespread use of concurrent
chemotherapy, and each trial tested the use of increasing
doses of radiation delivered by three-dimensional (3-D) con-
formal techniques. In a published phase I trial, Rosenzweig et
al.18 from the Memorial Sloan-Kettering Cancer Center re-
ported that doses as high as 84 Gy total were tolerable as long
as a normal tissue complication probability constraint was
kept at less than 25%. Their data suggested that survival was
improved in patients receiving 80 Gy or more. In a similarly
designed study of dose escalation based on normal tissue
toxicity predictions, Hayman et al.19 from the University of
Michigan escalated the dose to as high as 102.9 Gy using 3-D
conformal techniques and conventional fractionation. Local
failures were a significant mode of failure, but isolated
regional failures in clinically uninvolved and untreated lymph
node groups were uncommon. Finally, the RTOG carried out
a multicenter dose escalation study of radiotherapy either
alone or with induction chemotherapy and found that 83.8 Gy
was tolerable in patients with plans limiting the volume of
lung getting 20 Gy or more to less than 25%.20 No dose-
response relationship was observed, and the 2-year local-
regional control rate for the group that received 83.8 Gy was
only 55%.
Although these trials continue to mature, it is clear that
very high doses (as high as 100 Gy) of CFRT can be
delivered with 3-D conformal techniques. In separate analy-
ses, Mehta et al.21 and Machtay et al.22 showed that prolon-
gation of treatment time in lung cancer resulted in poorer
survival. For treatment prolongation beyond 5 to 6 weeks
total, patients lose 1% to 2% survival per day as a group
owing to accelerated tumor clonagen repopulation. This prob-
lem is the impetus for dramatically accelerated treatment
regimens including the continuous hyperfractionated acceler-
ated radiation therapy (CHART) regimen from Europe.23
The current standard of care for treating stage III
NSCLC involves giving radiotherapy concurrently with che-
motherapy. This strategy exploits the radiosensitization af-
forded by chemotherapy agents such as platinum-based drugs
when given concurrently with radiotherapy. An ideal radio-
sensitizer would preferentially sensitize tumor tissues more
than normal tissues. Although chemotherapy is not ideal in
this sense, it does afford more tumor kill at a given dose of
radiation compared with radiation alone at the same dose.
Unfortunately, normal tissues such as the esophagus are
subject to higher grades of acute toxicity from concurrent
chemoradiotherapy than from radiotherapy alone. Still,
with proper supportive care, this strategy is tolerable and
effective. In stage I NSCLC, the concurrent administration
of chemotherapy and radiotherapy is considered in more fit
patients, but there is no high level evidence supporting its
use. In medically inoperable patients, concurrent chemo-
therapy and radiotherapy might even be detrimental de-
pending on tolerance.
Protracted CFRT exploits differences in radiation dam-
age repair capacity between neoplastic and normal tissues
with the intent of providing opportunity for more interfraction
repair in normal tissues than tumor tissue. Increasing the dose
per fraction is hypothesized to erase this differential effect by
overwhelming tissue repair mechanisms in both tumor and
normal tissue. In turn, however, larger dose per fraction
treatments are clearly more potent at the same total dose level
than CFRT. Rather than exploit inherent biological repair
capacity to achieve a differential tumor versus normal tissue
effect, another strategy is to use technology (e.g., image
guidance and 3-D dosimetry) to simply avoid hitting normal
tissue as much as possible while still targeting the entire
tumor. This strategy has taken two forms: traditional hypofrac-
tionation and ablative fractionation. Traditional hypofraction-
ation involves using daily doses of more than 2.5 to 3 Gy but less
than 6 to 7 Gy per fraction. In a recently completed trial by the
Cancer and Leukemia Group B (CALGB 39904), the total dose
of CFRT was fixed at 70 Gy. The number of treatments was
successively lowered such that the dose per fraction increased.
Results of this trial with traditional hypofractionation are pend-
ing (Jeffrey Bogart, MD, Upstate Medical University, Syracuse,
NY, personal communication, December 2005).
Stereotactic body radiation therapy (SBRT) is a modern
therapy that uses such high dose per fraction over a few
fractions disrupting both cellular proliferative capacity and
cell function. A treatment that disrupts both cell division and
cell function is called ablative as originally related to the
administration of radioactive iodine for well-differentiated
thyroid cancer. The remainder of this article focuses on this
mode of treatment delivery.
A feared consequence of very large dose per fraction
treatments is known as toxic late effects. This type of toxicity
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includes devascularization, fibrosis, ulceration, and necrosis
and may not manifest until years after therapy. Nerves and
blood vessels are thought to be particularly prone to such late
effects. Tissues that form conduits or linear electrical circuits
are referred to as serially functioning tissues and include the
bowels, blood vessels, and nerves.24,25 These serially func-
tioning tissues may function with irreparable damage for
many months, even years, after the insult and then undergo
catastrophic failure. The current strategy for SBRT to mini-
mize the risk of such late effects is simply to treat the tumor
while employing technology to minimize the volume of
uninvolved normal tissues receiving a high radiation dose.
This rational exclusion of volume requires that patients be
selected who do not require prophylactic (adjuvant) radio-
therapy, that targeting accuracy is very high, that motion be
prudently accounted for, and that dose falloff to normal
tissues is very rapid in all directions.
Avoiding Normal Tissue Exposure with SBRT
Generally, we assume that ablative dose delivery to the
target alone is nontoxic. As such, toxicity observed after
treatment is related to the dose unintentionally deposited
outside the target. For ablative fractionation, this toxicity is
primarily a consequence of the dose delivered within 2 to 3
cm of the margin of the target. It is important that dose plans
for SBRT show extremely rapid falloff gradients in all direc-
tions from very high prescription dose levels to lower tolerant
dose levels as demonstrated in Figure 1. This shell or peel
around the tumor is at high risk of damage from SBRT, which
may ultimately lead to symptomatic toxicity. Avoiding tox-
icity is linked to the success in limiting the volume of this
transitional high dose shell surrounding the tumor.
Accounting for Motion
In brain radiosurgery, once the skull is immobilized and
referenced to the treatment device, the issue of intrafraction
tumor motion is negligible. Such is not the case when per-
forming SBRT. It is neither practical nor prudent to artifi-
cially stop all organ motion in the body. Of course such
motion may dramatically affect targeting accuracy. Insisting
that the tumor be included in the radiation portal throughout
the entire course of a treatment (which may last hours in some
cases) would therefore require that the aperture be signifi-
cantly enlarged compared with a nonmoving target as shown
in Figure 2.
Before accounting for motion, it must be first moni-
tored and quantified. Image guidance has been very helpful in
this regard. Generally, a surrogate is identified to help quan-
FIGURE 1. Typical dosimetry for
an early stage non-small cell lung
cancer stereotactic body radiation
therapy. PTV, planning treatment
volume.
FIGURE 2. Uncontrolled tumor motion re-
quires enlargement of a beam’s eye view radia-
tion portal to avoid target inaccuracy. Careful
assessment and control of motion dramatically
decrease normal tissue exposure.
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tify the actual tumor position. In the case of lung cancers, the
tumor outline itself may be recognized on fluoroscopy or
computed imaging. The motion map showing the target
position during all phases of the respiratory cycle can be
determined. Modern four-dimensional (4-D) scanners can be
very helpful for accurate assessment of these motion maps,
but they are not absolutely essential. Caution should be used
in systems that force the patient to breath in an “artificial”
fashion during simulation that is different from the expected
breathing pattern during treatment. When the tumor cannot be
visualized on fluoroscopy, the diaphragm is commonly used
as a motion surrogate. This practice can be problematic if the
correlation between tumor motion and diaphragm motion is
poor. At any rate, simply measuring the motion, even if done
very carefully with a 4-D computed tomography (CT) scan, is
not enough. The typical motion for a lung tumor around the
diaphragm involves 2 to 3 cm of excursion. Adding a 2- to
3-cm margin would limit dose delivery or increase toxicity,
which is unacceptable for SBRT. An accounting of the
motion is required to ultimately allow portal margins of not
greater than 1 cm as described in the following.
Three general categories of respiratory motion control
have been employed in SBRT to decrease volume irradiated.
These categories are tumor tracking or chasing, gating, and
respiratory inhibition. Tracking first requires an implanted
fiducial marker or other reliable tumor motion surrogate
correlated with all phases of the respiratory cycle. The marker
or surrogate, such as a point on the chest wall and a breathing
flow detector, drives the position of the radiation beam.26,27
Respiratory gating is a commonly practiced form of motion
control that also requires knowledge of tumor position within
a respiratory cycle. If the tumor location at an identified phase
within the respiratory cycle is confidently identified, then the
treatment is activated to irradiate only when the tumor is in
that position with small margin.28 Generally, gating occurs at
the end of expiration, which is a longer phase and relatively
stable. The final category of motion control is respiratory
inhibition in which the respiratory cycle is artificially manip-
ulated to facilitate minimizing margins. Two techniques
within this category have been used. Forced breath hold
would effectively “freeze” the tumor in a stable position that
is correlated with the treatment beams.29,30 Both inspiration
and expiration breath holding has been described. The beam
is only activated while the breath is held with the proper tidal
volume. Finally, the most commonly used method of motion
control is abdominal compression. This is a simple method in
which diaphragmatic excursion, the largest component of
respiratory motion, is limited by pressing uniformly on the
abdomen with an external device.31–33 Limiting diaphrag-
matic breathing forces the patient to use relatively more chest
wall breathing (expanding the chest wall by using the inter-
costal muscles). Although motion is never completely con-
trolled by this method, the relative increase in chest wall
breathing to diaphragmatic breathing substantially dampens
tumor motion, facilitating margin reduction.
Of the various methods described, both gating and
breath hold techniques require a period when the beam is on
and off. This duty cycle results in increased treatment time,
which may be problematic, especially if the beam output on
the radiation device is low. Furthermore, some methods are
difficult to tolerate for some patients. As such, choice of
motion control must be individualized to facilitate small
volume yet accurate treatment.
Dosimetry
Dosimetry for SBRT requires that the potent dose must
confidently hit the target while having very sharp falloff dose
gradients outside the region of the tumor. Depositing a high
dose of radiation within the target volume will, unavoidably,
require a certain minimal integral dose to be deposited in the
surrounding normal tissue as beams traverse the tissue around
the tumor. To minimize the volume of the high-dose shell
around the target during SBRT, it is necessary to aim at the
target from many more directions than is typically done for
CFRT, where this issue is less relevant. Generally, this is
accomplished by using multiple fields (e.g., 10), multiple
degrees of arc rotations, noncoplanar fields, and nonopposing
fields.34 As shown in Figure 1, this type of dosimetry con-
struction effectively mimics radiosurgery in the brain. For
treatment in the brain, an organ both poorly tolerant and less
effective at repair, high entrance dose is avoided to reduce
global effects such as memory problems, whereas a high dose
outside of the target is avoided to reduce radionecrosis. SBRT
is a logical extension of brain radiosurgery, much more than
an extension of CFRT or intensity-modulated radiotherapy
(IMRT). Mimicking brain radiosurgery, with the added
charge of accounting for inherent organ motion, is the best
approach to delivering safe and effective SBRT.
Target Volumes for SBRT in the Lung
Tumor target delineation is generally based on pulmo-
nary window CT scans. The gross tumor volume (GTV)
target is either not expanded or only minimally expanded to
create a corresponding clinical target volume (CTV) for
microscopic extension. It is assumed the isotropic dose falloff
at dose levels near the prescription dose will be adequate to
eradicate tumor tentacles beyond the GTV. Only tissues that
have obvious tumor involvement are included in the target
because adding additional tissue when in doubt (a practice
common in the teaching of CFRT delivery) may dramatically
increase treatment toxicity with SBRT. If in doubt about
targeting and tumor involvement, it is prudent to fuse in other
imaging platforms such as positron emission tomography
(PET) or magnetic resonance imaging (MRI) as appropriate
to better define the tumor. Again, the proper motivation in
SBRT would be to find ways to confidently exclude unin-
volved tissues, making the target as compact as possible.
The GTV is expanded to the planning treatment volume
(PTV) based on individual assessment of motion. Ideally,
measures to control setup errors and motion would be imple-
mented to limit this GTV-to-PTV expansion to 1.0 cm or less.
In striking distinction from CFRT, there is no effort in
planning SBRT to construct uniform target dose distribution.
Instead, the dosimetrist should require that the target is
adequately covered by the prescription dose, but concentrate
on optimizing the dose falloff outside the target and respect-
ing normal tissue dose constraints.
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RESULTS
The Indiana University Dose Escalation Trials
Using the treatment process described above, research-
ers at Indiana University performed a formal phase I dose
escalation toxicity study with 47 patients with medically
inoperable lung cancer.35,36 The starting dose was 8 Gy per
fraction  3, 24 Gy total. All patients were treated with three
fractions at all dose levels. Independent dose escalation trials
were carried out in three separate patient groups: patients
with T1 tumor, patients with T2 tumor less than 5 cm, and
patients with T2 tumor 5 to 7 cm. There was no restriction
regarding the location of the tumor in the lung as both central
and peripheral tumors were treated. There were waiting
periods built into the design to observe toxicity even after the
acute period. A total of seven dose levels were tested. The
maximal tolerated dose (MTD) was never reached for T1
tumors and T2 tumors less than 5 cm despite reaching 60 to
66 Gy in three fractions. For the largest tumors, dose was
escalated all the way to 72 Gy in three fractions, which
proved to be too toxic. Dose-limiting toxicity in that subset
included pneumonia and pericardial effusion. Therefore, the
MTD for tumors 5 to 7 cm in diameter was 66 Gy in three
fractions, whereas the MTD for smaller tumors lies at an
undetermined level beyond this dose. Classic radiation pneu-
monitis (fever, chest pain, shortness of breath, dry cough, and
infiltrative radiographic findings), which had been errone-
ously predicted to be the dose-limiting toxicity, only occurred
sporadically.
At the lower doses (i.e., 24–36 Gy in three fractions),
very impressive tumor responses with little normal tissue
effects were observed by 3 months, as shown in Figure 3.
Unfortunately, many of these patients ultimately had tumor
recurrence. A dose-response curve for local control using
SBRT in lung cancer from these data is shown in Figure 4. As
the dose was increased to more than 42 to 48 Gy, striking
imaging changes began to appear near the treated tumor by
approximately 6 to 12 months, as shown in Figure 5. This
seemed to be related to a bronchial toxicity, which was not
commonly described with CFRT. The changes with high
doses were commonly seen on imaging studies but not always
symptomatic. Radiographic changes by themselves were not
considered dose limiting. In many cases, the radiographic
changes mimic tumor recurrence. With no salvage therapy in
this population, patients were followed without treatment.
Repeat PET scans and biopsy samples showed no evidence of
tumor recurrence in the majority of patients treated at the
higher dose levels. In the end, a dose of 60 to 66 Gy in three
fractions was determined to be reasonably safe for enrolled
medically inoperable NSCLC patients.
The Indiana University Phase II Study
Upon completion of the phase I study and finding a
clearly potent dose for SBRT, the Indiana group embarked on
a 70-patient phase II study in the same population. The phase
II study was aimed at validating toxicity in a larger patient
population and determining efficacy (local control or sur-
vival) using a total dose of 60 Gy in three fractions for the
small tumors and 66 Gy in three fractions for the large tumors
(35 patients in each group). The target control rate for the
statistical power calculation was 80%, which is dramatically
higher than the typical 30% to 45% control seen with CFRT.
This protocol was funded by a grant from the U.S. National
Institutes of Health. As such, it was required to have exten-
FIGURE 3. Nineteen-month tumor
response after low to moderate
dose level stereotactic body radia-
tion therapy (SBRT) in lung cancer.
FIGURE 4. Dose-response curve for local control after ste-
reotactic body radiation therapy using three fractions in a
prospective trial.
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sive processes in place for ensuring patient safety and mon-
itoring the quality of data collected. All high-grade adverse
events (e.g., emergency department visits, surgical proce-
dures, hospitalizations, and deaths) were reviewed by an
independent data safety–monitoring panel to determine
whether the event was treatment related (i.e., treatment-
related toxicity). In addition, this panel was responsible for
final scoring of efficacy such as determining local recurrence.
The preliminary results of this phase II trial are in
press.37 The actuarial 2-year local control for this potent dose
regimen is 95%, as shown in Figure 6, and isolated hilar or
mediastinal nodal relapse is extremely rare despite clinical
staging. The overall 2-year survival for this frail population is
poor at 56%, with most of the deaths related to comorbid
illness rather than disease progression or toxicity. The proto-
col placed no time limits on scoring treatment-related toxicity
and many late toxic events have been recorded. Fewer than
20% of patients have experienced high-grade toxicity, con-
firming the phase I model. However, an important observa-
tion was reported in a presentation at the annual American
Society for Therapeutic Radiology and Oncology (ASTRO)
meeting in October 2005 in Denver, CO. Interim analysis
showed that severe toxicity (grades 3–5) was significantly
more likely in patients treated for tumors in the regions
around the proximal bronchial tree or central chest region. In
fact, the risk of severe toxicity is 11 times greater when
treating central tumors compared with peripheral tumors.
When local failures occur, they tended to occur long
after completion of therapy (in the range of 1–3 years),
indicating that reports with short follow-up after SBRT most
likely have not observed all local failures. The conclusions
reached from this phase II trial is that local control is very
high with the potent dose employed. Local failures still occur,
and typically years of follow-up are required to observe these
local failures. Toxicity is substantial if treating tumors in the
central chest region, probably negating any positive benefits
of local control. Toxicity after SBRT occurs late, similar to
local recurrence. Patients should be followed for long periods
before drawing conclusions from prospective trials.
Other Institutional Experience
Whyte et al.38 reported the preliminary results of a
phase I study conducted at two institutions using a robotic
delivery device for early-stage lung cancer. They used a
single dose of SBRT prescribing 15 Gy to the margin of the
tumor in 15 patients with primary lung cancer. With a mean
follow-up of 7 months, toxicity was considered acceptable.
Song et al.39 reported an experience in which they used a
normal tissue complication probability formulation to guide
FIGURE 5. Tumor and normal tis-
sue response after high-dose level
stereotactic body radiation therapy
in lung cancer demonstrates post-
treatment bronchial injury with
downstream effects. Rx, treatment.
FIGURE 6. Kaplan-Meier local tumor recurrence free sur-
vival for a phase II trial of stereotactic body radiation therapy
using 60 to 66 Gy given in three fractions.
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dose escalation to 45 Gy in three fractions. They concluded
that in contrast to CFRT, radiation pneumonitis is not the
dose-limiting toxicity for SBRT. Beitler et al.40 reported on a
retrospective experience treating 75 patients with a variety of
dose levels (median, 40 Gy in five fractions). They found that
survival was related to tumor size at time of treatment.
Cooperative Group Trials within the RTOC
Although single institution trials are often the forum for
the innovation, piloting, and refining of novel cancer thera-
pies, promising treatments should ultimately be tested in
multicenter trials. Multicenter trials are typically performed
by government-sponsored or investigator-independent coop-
erative groups specializing in quantifying outcomes fairly.
Bias involved in selection of patients, the conduct of treat-
ment, the assessment of control and toxicity, and the deter-
mination of outcome is best controlled in multicenter coop-
erative group trials. The multicenter testing of therapy avoids
the conflict of interest associated with the single-institution
experience. If the novel therapy is important for future im-
plementation on a wide scale, it must be documented that
physicians and staff outside the originating center can be
trained to perform the therapy. It must be demonstrated that
the results are consistently reproducible. In the end, the single
or limited institution experience creates the novel therapy
while the multicenter (and particularly the cooperative group)
experience finds the proper place for the therapy in the
treatment arsenal. The ultimate cooperative group trial, the
large phase III randomized trial, often redefines the standard
of care.
In 2004, after several years of planning, the Lung
Committee of the RTOG finalized plans to carry out a
multicenter trial of SBRT in patients with medically inoper-
able NSCLC. RTOG 0236 using SBRT for medically inop-
erable lung cancer in patients with peripherally situated
tumors completed its accrual of 52 patients. This trial was
based on the preliminary data from Indiana University using
60 Gy in three fractions for T1, T2, and peripheral T3 tumors
less than 5 cm in diameter. Extensive accreditation, conduct,
and dosimetry constraints were developed in the RTOG
Lung, Physics, and Image Guided Therapy Committees to
form a basis for meaningful quality assurance and consistent
treatment for a multicenter trial. Three toxicity analyses were
performed during the trial that showed no excessive toxicity
warranting trial closure. Results from RTOG 0236 will not be
available for some time. It will be followed by RTOG 0624,
a trial giving adjuvant systemic therapy along with SBRT in
an effort to reduce the risk of patients at higher risk of
systemic relapse. Another trial in patients with centrally
situated tumors, RTOG 0633, is being planned that will use a
more gentle fractionation scheme for medically inoperable
patients.
RTOG 0618 is in the finalization process for patients
with documented NSCLC who are medically suitable for
surgical anatomical resection. This is a dramatic departure
from previous trials in North America in which only frail
medically inoperable patients were enrolled in SBRT trials.
This trial, patterned after RTOG 0236, will include an early
assessment for surgical salvage in people with less than ideal
response. As such, SBRT is being studied in broader popu-
lations with early-stage NSCLC building on the existing
prospective testing.
DISCUSSION
Clinical Opportunity: SBRT for Early-Stage
Operable Lung Cancer
To date, prospective trials using SBRT in North Amer-
ica have specifically selected patients with medically inoper-
able disease due to preexisting comorbid illnesses. This is a
population whose outlook has been poor due to both disease
progression after generally less effective therapy (e.g.,
CFRT) and progression of health problems associated with
their underlying severe comorbidities (e.g., severe emphy-
sema, severe heart disease). Local cancer progression as a
factor in the demise of these patients has been dramatically
reduced with SBRT compared with historical experience,
making SBRT an attractive new treatment option. Further
refinement of SBRT via refinements related to dose and
combination therapy with systemic agents is ongoing, as
mentioned in the previous paragraphs. However, there are
limits to the level of progress attainable in this at-risk popu-
lation of medically inoperable patients because death from
cancer is just one of many competing causes of morbidity and
mortality.
Although it was logical to initiate the implementation
of SBRT in the medically inoperable population, a much
greater opportunity for helping patients exists with investiga-
tion of the same therapy in operable patients. The category of
operable patients is a much larger population, accounting for
nearly 20% of all lung cancer diagnoses. The standard ther-
apy for stage I operable patients, anatomical resection with
lobectomy or pneumonectomy, is a very good therapy with
high cure rates. Still, this surgery is a difficult ordeal for many
patients, particularly those considered marginally operable,
on the fringe of health status between generally healthy and
blatantly medically inoperable. Many of these patients are
treated surgically but with a compromised resection such as a
wedge or segmentectomy putting them at high risk of local
progression. If SBRT is confirmed to have equivalent or
better efficacy than surgery, then the use of SBRT would
allow patients to be treated with a noninvasive outpatient
therapy avoiding surgery-associated pain, exposure to noso-
comial infection, inpatient and intensive care unit costs, lost
work and income, loss of respiratory capacity, and chronic
pain. Admittedly, surgical procedures have evolved dramat-
ically with the use of video-assisted and minimally invasive
procedures. Still, patients are ideally presented with more
than one established options with proven efficacy, allowing
them to customize their therapy based on all factors important
to them.
Requirements for SBRT to Match Surgery
Although the issue is still debated, the predominant
benefit of surgery using anatomical resection with lobectomy
over limited surgeries such as wedge resection is related to
improved local control. Although lobectomy also removes
lymph nodes that could theoretically lead to regional failure,
Journal of Thoracic Oncology • Vol. 2, No. 7, Supplement 3, July 2007 North American Experience with SBRT in NSCLC
Copyright © 2007 by the International Association for the Study of Lung Cancer S107
the one prospective, randomized study found that the benefit
in survival was mostly a consequence of improved local
control.5 Local control with lobectomy in surgical series
carried out in North America is typically 85% to 95%
compared with only 50% to 70% for wedge resection.13 As
such, for SBRT to become an alternative to lobectomy, it too
must attain local tumor control in approximately 90% of
patients.
This requirement of local control of 90% in medically
operable patients has strong implication of the necessary
treatment dose. Dose and toxicity with SBRT are strongly
related. It may be perfectly reasonable to use a safer dose of
SBRT in an informed medically inoperable patient that may
attain, for example, an 80% local control rate to avoid the
toxicity of higher dose levels. With so many competing
causes of death, the 80% control dose level may balance
favorably with the avoidance of aggravating preexisting mor-
bidities with higher radiation dose. Still, for operable patients,
the greatest threat to their survival is recurrence of cancer,
putting a greater burden on the therapy to ultimately control
the known disease. The only prospective dose escalation trial
with documented local control assessment carried out for
SBRT in lung cancer to date is the Indiana University phase
I study. This trial showed that total dose in the range of 54
to 66 Gy in three fractions is required to achieve long-term
local control in 90% or more of treated patients, as shown
in Figure 4. That same trial showed that dose levels in the
range of 36 to 48 Gy in three fractions achieve high rates
of local control in the 60% to 80% range, much better than
the 30% to 50% local control associated with CFRT.
However, for patients treated in North America, prospec-
tive evidence indicates that doses lower than 50 Gy in
three fractions will not control the primary lung cancer
adequately to make a favorable comparison of SBRT with
best available surgery.35,36
Interestingly, Japanese investigators using more modest
treatment dose levels in prospective testing have reported
trials with adequate follow-up showing local control of
greater than 90% with considerably lower SBRT dose pre-
scriptions. For example, Nagata et al.41 from Kyoto Univer-
sity reported a series of 45 patients treated with a dose of 48
Gy in four fractions to the isocenter. This dose is biologically
less potent than the dose fractionation schemes used in
prospective North American trials (60–66 Gy in three frac-
tions) or and roughly equivalent to European trials (45 Gy in
three fractions). Still, Nagata et al. reported effectively no
in-field local failures (100% local control) with this dose,
which is in contrast to the results published from North
America and Europe, where local control is only 70% to 80%
with dose prescriptions in the this range, as shown in Table 1.
The techniques used by Nagata and colleagues for immo-
bilization, targeting, dosimetry, and treatment conduct are
essentially identical to those used at Indiana University.
This same dose prescription piloted at Kyoto University is
being tested in the larger Japan Clinical Oncology Group
0403 trial for peripheral T1N0 stage I patients, which is
still accruing patients. A clue to the likely explanation for
these conflicting results between experienced centers in
North America and Asia may be found in the overall
survival results. Two-year overall survival in the Nagata et
al. series was more than 80%, in striking contrast to the
Indiana phase II study and European experiences, in which
only approximately 50% of patients are alive. Indeed, the
Nagata et al. series survival for medically inoperable
patients is quite comparable with that of the series describ-
ing operable patients in North America. As such, it seems
that these are different populations, indicating a striking
difference in patient selection.
Although the exact mechanisms for achieving local
control remain to be discovered through thoughtful basic
science and translational research, achieving local control for
early-stage patients is the most effective route to avoiding
death from cancer. As such, for operable patients, the goal of
SBRT should be to eradicate the local tumor. The upcoming
RTOG phase II trial for operable patients will first provide a
very potent dose SBRT treatment (60 Gy in three fractions)
and subsequently make frequent and ongoing assessments of
the status of local tumor viability. In the first 20 patients
enrolled (lead-in phase), each patient will undergo needle
biopsy at 6 weeks after therapy. If tumor cells are visible,
the patient will be referred for salvage surgery within 12
weeks of completing SBRT. The resected tumor specimen
will be assessed for viability. In addition, all patients
enrolled in the trial will have CT and PET assessment of
tumor response. Poor responders will again be referred for
salvage surgery. These safety net inventions are important
to ensure that this generally curable population is not
harmed by a trial of a newer and potentially less effective
therapy. Still, with the excellent actuarial local control
observed with SBRT in medically inoperable patients, it is
hoped that a similar experience will be observed with
operable patients.
To date, none of the trials using SBRT for early-stage
lung cancer have included pathological assessment of nodal
status in the hila or mediastinum before therapy. Patients in
TABLE 1. Local Control in Early Stage Non-small Cell Lung
Cancer
Author/Ref. Treatment
Local
Control
Single
Fraction
Equivalent
Dose (Gy)*
North America/Europe
Timmerman et al. (2006)37 20–22 Gy  3 95% (2 yr) 56–62
Bauman et al. (2006)42 15 Gy  3 80% (3 yr) 41
Fritz et al. (2006)43 30 Gy  1 80% (3 yr) 30
Nyman et al. (2006)44 15 Gy  3 80% (crude) 41
Zimmerman et al. (2005)45 12.5 Gy  3 87% (3 yr) 43.5
Timmerman et al. (2003)35;
McGarry et al. (2005)36
18–24 Gy  3 90% (2 yr) 50–68
Asia
Xia et al. (2006)46 5 Gy  10 95% (3 yr) 32
Hara et al. (2006)47 2006 30–34 Gy  1 80% (3 yr) 30–34
Nagata et al. (2005)41 12 Gy  4 94% (3 yr) 42
*See Appendix.
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North American prospective trials have been clinically staged
with CT and PET before treatment. Surgical series have
shown upstaging upon pathological assessment (e.g., medi-
astinoscopy, open lymph node dissection) of as many as 20%
of patients compared with the presurgical clinical assessment
of stage. The implication, then, would be that 20% of patients
would fail in the intrapulmonary, hilar, or mediastinal lymph
nodes, probably as a first site of failure, in clinically staged
patients. The clinical experience for SBRT in treating clini-
cally staged patients that includes careful follow-up of the
chest lymphatics, however, shows a less than 5% incidence of
isolated lymph node failure after a treatment that includes
only the primary tumor in the lung. The explanation for this
may be related to better clinical staging in the PET era.
Alternatively, it is possible that there is an immune effect
with SBRT (e.g., autovaccination) that leads to natural
destruction of microscopic tumor deposits hiding within
lymphatics. Although this is speculation, nonetheless,
there does not seem to be strong rationale to mandate
pathological staging for clinical stage I lung cancer before
treatment with SBRT as the risk of isolated lymph node
failure is very low.
Fallacy: SBRT Is Like a Wedge Resection
Using Radiation
Many practitioners have erroneously conceptualized
SBRT to ablative dose levels as a radiation equivalent of
wedge resection. This is a less than flattering perspective
because it leads to the dismissal of SBRT as a viable alter-
native to best surgical care. Wedge resection as carried out in
North America is a compromised and inferior surgical pro-
cedure for most patients with early-stage lung cancer. Local
control reports after wedge resection are as low as 50% and
rarely higher than 85%. This is a consequence of the technical
difficulties in obtaining an adequate bronchial margin while
simultaneously trying to spare normal lung. As such, the
tumor commonly recurs along the suture line after wedge
resection. The new American College of Surgeons Oncology
Group trial using brachytherapy along the suture line after
wedge resection is directly trying to address this well-known
problem. As noted above, the benefit of anatomical resection
with lobectomy or pneumonectomy follows from achieving
better margin on the primary tumor, not from removing
lymph nodes. In striking contrast to wedge resection, SBRT
gives adequate margin in all directions from the tumor. In
addition, in properly constructed SBRT plans using photons,
there is an isotropic dose falloff gradient that ensures that
even microscopic tentacles coming from the tumor are deliv-
ered a potent dose. As a result, local control appears consid-
erably better with ablative dose SBRT than with wedge
resection. Indeed, SBRT is not like a wedge resection, rather
it is more like a lobectomy in terms of achieving high rates of
local control.
CONCLUSIONS
Regarding the implementation of SBRT in medically
inoperable patients with stage I lung cancer treated in North
America, the following conclusions are reached based on
mature prospective trials:
1. The maximal tolerated dose for peripheral primary
tumors less than 7 cm is 60 to 66 Gy in three
fractions.
2. The maximal tolerated dose for centrally located
primary tumors less than 7 cm is unknown but is
exceeded by doses of 60 to 66 Gy in three fractions.
3. A prescription dose less than 54 Gy in three frac-
tions is associated with maximal local control of
approximately 70% to 80% for patients treated in
prospective trials with adequate follow-up in North
America and Europe.
4. A prescription dose of 54 Gy or more in three
fractions has been demonstrated to achieve local
control in more than 90% of treated tumors in
prospective testing.
5. Despite clinical staging, isolated hilar and medias-
tinal nodal failures occur in less than 5% of patients
after SBRT.
6. Despite staging with whole body PET scans, ap-
proximately 20% of patients develop distant meta-
static disease.
7. Although it is well-known that toxicity after large
dose per fraction treatment occurs late, it is also
recognized that tumor recurrence likewise occurs
late after treatment with the median time to recur-
rence of 16 to 24 months after therapy.
8. Despite excellent local control after SBRT, patient
survival for medically inoperable early-stage lung
cancer is very poor, mainly due to severe and life-
threatening coexisting morbidities and the eventual
appearance of metastatic disease.
All the prospective clinical testing of SBRT in North
America has been conducted in medically inoperable pa-
tients. As a group, medically inoperable patients in North
America appear to have a very poor prognosis with overall
survival considerably less than that observed in patients
deemed medically inoperable in Japan and China. In general,
this patient selection may explain the differences in tumor
control observed using similar SBRT dose and technique
between the two regions. To compare favorably with optimal
surgical therapy for operable patients, SBRT must achieve
local control of 90% or greater. As such, prescription dose
levels for patients treated in North America must be consid-
erably higher than that used in Asian series. A prospective
phase II trial in operable patients about to start in North
America (RTOG 0618) will help answer the question of
whether SBRT is feasible, tolerable, and efficacious.
That fact cannot be avoided that failure to control the
primary tumor is the single greatest problem in radiotherapy
of lung cancer. There are a large number of frail patients who
have localized lung cancer, and this population will likely
grow with wider acceptance of CT screening. Both more
prospective clinical testing and more biological investigation
are necessary to move SBRT forward as a noninvasive local
therapy for lung cancers. In the end, it is hoped that SBRT
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will constitute an alternative to surgical resection for operable
early-stage lung cancer patients. Realizing such an opportu-
nity, however, will require ongoing prospective clinical test-
ing such as has been initiated by the RTOG in North America
to ensure realistic assessment of benefit and harm to patients
with early-stage lung cancer.
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APPENDIX
The linear quadratic (LQ) was developed in the context
of treatment realities of the time.48 In that era, radiotherapy
was being delivered, mostly by necessity, in small daily doses
in the range of 1.8 to 6 Gy to fairly high cumulative doses in
the range of 30 to 70 Gy. This type of radiation, commonly
called (CFRT, delivered daily treatments in a portion of the
cell survival curve (plotting cumulative dose versus log of
clonagenic survival) called the shoulder. The LQ model fits
the survival curve very well around the shoulder as it was
designed from a linear and quadratic power series regression
in this small daily dose range. However, the LQ model
predicts continuously curving survival curve in the high-dose
range due to domination of the power series by the quadratic
term. This is in contrast with the empirical data that show that
the survival curves of mammalian cells become straight lines
in the high-dose range.49 In the era in which all radiotherapy
was delivered using CFRT, with dose per fraction well within
the shoulder region, this discrepancy was of little signifi-
cance. Within the SBRT formalism, where daily doses as
high as 20 to 30 Gy are routinely delivered, the LQ model
may grossly overestimate the effect of radiation. In an early
paper, Fowler48 emphasized this point stating, “LQ is not
intended for doses higher than 8–10 Gy. In any case, LQ is
simply a low-dose approximation to equations that do be-
come straight exponentials at higher doses.” Attempts to
modify the LQ model for the SBRT setting have been
offered50; however, it may be most prudent to consider
alternate models fitting the experimental data.
Biologically effective dose (BED) is a method by
which comparison of different dose-fractionation schemes is
made by correlating them with the idealized dose that would
achieve the same biological effect if delivered in infinitesi-
mally small fractions.51 BED is based formally on the LQ
model and assumes extrapolations of the LQ model beyond
its applicable range are valid as well. BED has been used to
compare dose-fractionation schemes for SBRT even when
dose per fraction is beyond the 8 to 10 Gy limit assigned by
Fowler.52,53 This is problematic because any parameter based
on the LQ model will systematically overstate the potency of
increasing daily doses to absurd levels, both for normal tissue
toxicity and tumor control predictions.
Here, we propose an alternate method to compare
various dose-fractionation schemes, which may be more
relevant in the SBRT setting. This formalism finds basis in
the multitarget model of describing the cell survival curve
rather than the LQ model. Four simple assumptions are made
before proceeding:
1. The survival curve becomes a straight line after a
high transition dose beyond the shoulder in the
biologically ablative dose range and beyond.
2. The dose per fraction used in the SBRT setting lies
within the straight portion of the survival curve.
FIGURE 7. Idealized cell survival curve plotting dose versus
log of clonagenic survival for single and three fraction treat-
ments using large dose per fraction. SFED, single fraction
equivalent dose. See text for details.
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3. With each fractionation delivered under the SBRT
formalism, the shoulders of the survival curve re-
peat, given sufficient time between fractions to re-
pair sublethal damage.
4. The in vitro cell kill correlates with clinical out-
comes (e.g., local tumor control).
In Figure 7, OA describes the cell survival curve
achieved by a single ablative fraction, whereas OC is the cell
survival curve achieved by multiple (in this case, three) equal
fractions. Line CD is the isoeffect line (effect  cell kill).
Therefore, length of BD is the single fraction equivalent dose
(SFED), defined as the single fraction dose that would
achieve the same cell kill as the multiple SBRT fractions. The
difference between the cumulative dose, D, and SFED is
given by the length of BC. This is simply Dq  (N  1),
where Dq is the quasithreshold dose of the multitarget theory
and N is the number of fractions.
Radiosensitivity of human lung cancer lines have
been characterized in vitro using doses as much as 12
Gy.54–57 The NSCLC lines demonstrate shoulders typically
larger than those of the small cell lung cancer lines. The
extrapolation number (n) for NSCLC ranges from 1.2 to
9.5, whereas the D0 ranges from 1.0 to 1.6. Dq, given as
logen x D0, ranges from 0.2 to 3.2, with most of the cell
lines displaying Dq within 1.5 to 2.5 range. We populated
the Table 1 using Dq of 2.
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